The Week in Review: December 15 – December 22, 2017

Friday, December 22, 2017 News Recap: Eight Genotypes: Did you know that there are now 8 genotypes and 84 subtypes of HCV that have been identified?  On the one hand this is terrible news; but on the other, a study presented at AASLD 2017 found that Vosevi was effective against them all.  Eight Genotypes and 84 Subtypes of HCV. Telemedicine: Did you know that Project ECHO (Extension for Community Health Outcomes), a fast-growing international tele...

Is Project ECHO the Telemedicine Model That Healthcare Is Missing?

A fast-growing international program, Project ECHO uses telemedicine to help rural and remote providers learn from specialists to manage care for their complex patients. A telemedicine platform developed about 15 years ago in New Mexico is now helping thousands of doctors across the country learn from specialists and manage care for patients with complex conditions. Project ECHO (Extension for Community Health Outcomes) uses a hub-and-spoke model to co

Eight Genotypes and 84 Subtypes of HCV

The hepatitis C virus (HCV) is classified into 7 genotypes and 67 subtypes. Knowing the HCV genotype and subtype has been really important in determining the optimal treatment regimen. A study presented at The AASLD Liver Meeting 2017 – “Identification of Novel HCV Genotype and Subtypes in Patients Treated with Sofosbuvir Based Regimens” – found 17 novel HCV subtypes and 1 novel HCV genotype, unrelated to each other and to previously described HCV subtype

Should uninfected patients accept hepatitis C-infected livers to reduce waiting time?

Study suggests that antiviral drugs may allow safe transplantation of HCV-positive livers into uninfected recipients. A modeling study by Massachusetts General Hospital (MGH) investigators finds that the availability of directly-acting antiviral (DAA) drugs to treat hepatitis C virus (HCV) infection could allow the transplantation of livers from HCV-positive donors into HCV-negative recipients without posing undue risk. The team's report will appear i

Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults

Data published in the Journal of the American Geriatrics Society suggest direct-acting antivirals (DAAs) are safe and effective at achieving a sustained virologic response in older adults with hepatitis C virus (HCV)-related fibrosis or cirrhosis. HCV clearance is essential in improving disease outcomes in the general population, but data on reducing liver-related complications and increasing life expectancy in older adults are limited. The researchers

The Week in Review: December 8 – December 15, 2017

Friday, December 15, 2017 News Recap: 8 updates on liver transplantation outcomes for 2017: Over the past year, researchers and physicians have reported changes among the leading indications on the liver waitlist and improvements in transplantation outcomes. In this article, Healio.com/Hepatology presents recent reports on waitlist mortality risks, improved pediatric liver transplantation outcomes, and the positive effects of HCV treatment on transpl...

8 updates on liver transplantation outcomes for 2017

Liver transplantation is a necessity for many chronic liver diseases, including hepatocellular carcinoma, chronic hepatitis C, and alcoholic liver disease. Over the past year, researchers and physicians have reported changes among the leading indications on the liver waitlist and improvements in transplantation outcomes. In this article, Healio.com/Hepatology presents recent reports on waitlist mortality risks, improved pediatric liver transplantation o...

Liver Damage Worse in Women With HBV/HCV Coinfection, Risky Drinking

Coinfection with hepatitis B and C virus (HBV/HCV) combined with risky alcohol consumption enhances liver damage mechanisms to a greater extent in women than in men, according to a recent study in PLoS One. Hepatitis infection and risky drinking are major risk factors for liver disease, and coinfection with both HBV and HCV is more likely to progress to cirrhosis than single infections. Pooled data from 2 national surveys in Italy allowed the estimation o

Liver cancer incidence after HCV therapy linked to risk factors, not treatment

Direct-acting antiviral treatment for hepatitis C did not correlate with an increased risk for hepatocellular carcinoma in a large cohort study of both treated and untreated patients with or without cirrhosis. Those with incident HCC after DAA treatment had higher risk factors at baseline. “There was no increased risk for HCC as a result of having received DAA therapy whatsoever,” Raymond T. Chung, PhD, director of Hepatology and Liver Center at Massachus

The Week in Review: December 1 – December 8, 2017

Friday, December 8, 2017 News Recap: URGENT BC Patient and Caregiver Input Request: Vosevi. We need to hear your voice! Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir, velpatasvir, and voxilaprevir (SOF-VEL-VOX or Vosevi™) for Genotypes 1-6. Personal Stories This week we have two great stories of triumphing over HepC: Aidain’s ‘I will never forget the day I found out I had hepatitis c’, and Patric...